Neura Health and LillyDirect Partner to Tackle Neurologist Shortage

NEW YORK, NY – April 23, 2026 – Virtual neurology clinic Neura Health announced a new collaboration with LillyDirect, the direct-to-consumer digital platform from pharmaceutical giant Eli Lilly. The partnership aims to provide patients suffering from migraines with rapid access to board-certified neurologists, bypassing a healthcare system bottleneck that often leaves them waiting months for specialized care.

Through a dedicated portal on the LillyDirect site, individuals can now connect directly with Neura Health for evaluation, diagnosis, and ongoing treatment management. The move represents a significant step in leveraging telehealth to address the critical shortage of neurology specialists in the United States and reflects a broader strategic shift among pharmaceutical companies to build comprehensive patient care ecosystems.

A Digital Lifeline for Migraine Sufferers

For the more than one billion people affected by migraine globally, timely access to care is not a luxury but a necessity. Yet, in the U.S., the path to a specialist is often fraught with delay. With an average wait time of four to six months to see a neurologist, patients are frequently left to manage debilitating symptoms that can severely impact their quality of life and ability to work. The new partnership aims to dismantle this barrier, with Neura Health offering appointments typically within seven days.

This access gap is a direct result of a severe and widening provider shortage. “Today, the U.S. faces a significant shortage of neurologists, and that gap continues to widen as patient need outpaces provider capacity,” said Elizabeth Burstein, CEO and Co-Founder of Neura Health. “Migraine is one clear example of the access gap — there is roughly one specialist for every 83,000 patients. As a leading cause of disability worldwide, delays in treatment can lead to increased emergency department visits, prolonged symptoms, and reduced quality of life.”

The scale of the challenge is staggering, with over 145 million Americans living with some form of neurological condition. By creating a faster pathway from symptom onset to diagnosis and treatment, the collaboration between Neura Health and LillyDirect seeks to mitigate the personal and economic toll of untreated chronic conditions like migraine.

Lilly's Strategic Pivot to Patient Ecosystems

This partnership is also a telling move for Eli Lilly and its digital-first strategy. Launched in January 2024, LillyDirect was designed to simplify the patient experience by providing direct access to select Lilly medicines, telehealth services, and home delivery for conditions like obesity, diabetes, and migraine. By creating a direct-to-consumer channel, Lilly aims to gain more control over pricing and distribution while enhancing patient engagement and treatment adherence.

Neura Health is the latest addition to a growing network of specialized digital health providers on the LillyDirect platform, which already includes partnerships with companies like 9amHealth for diabetes and Form Health for obesity. This ecosystem approach signifies a fundamental evolution in the role of pharmaceutical companies, moving them from pure drug manufacturers to integrated players in the patient care journey.

By embedding telehealth providers directly into its platform, Lilly is not just facilitating access to its own medications but is also building a comprehensive support system around the patient. This strategy allows the company to gather valuable data on treatment pathways and outcomes, create a more loyal customer base, and establish a competitive advantage in a crowded market. The inclusion of Neura Health signals Lilly’s deep investment in the neurology space, an area where it has also recently expanded LillyDirect resources to include educational support for Alzheimer's disease.

Beyond the Pill: A Comprehensive Virtual Care Model

Neura Health distinguishes itself by offering more than just a quick consultation. The New York-based company, which has raised $22 million in venture funding, operates as a full-service virtual neurology clinic. Its model is built on providing continuous, comprehensive care that extends well beyond the initial appointment. This “wraparound” support is a key factor in its clinical success and a major differentiator in the crowded telehealth market.

Patients using the platform receive personalized care plans, secure messaging with their care team, integrated prescription management, and access to condition-specific educational resources. The Neura app also includes sophisticated symptom tracking tools, allowing both patients and their neurologists to monitor progress and adjust treatment plans in real time. This high-touch, data-driven approach has yielded impressive results, validated by peer-reviewed research published in journals such as Headache and the Journal of Clinical Medicine. Studies of Neura’s care model show a 73% reduction in emergency and urgent care visits, a 55% decrease in monthly headache days after 90 days, and a 66% improvement in patients' overall impression of their symptoms.

Having already served over 57,000 patients nationwide, Neura’s platform covers a wide spectrum of neurological conditions beyond migraine, including epilepsy, chronic pain, stroke recovery, and memory disorders. This comprehensive scope positions it as a robust solution for patients, employers, and the major health plans it partners with, including Aetna, Cigna, and Medicare.

Navigating the New Frontier of Tele-Neurology

The collaboration arrives at a pivotal moment for neurology. The COVID-19 pandemic dramatically accelerated the adoption of telehealth, proving its efficacy and acceptance among both patients and providers. The American Academy of Neurology has endorsed a standardized virtual neurological exam, cementing telehealth's role as a legitimate and essential component of modern neurological practice.

With reimbursement pathways now well-established, as evidenced by Neura’s contracts with major national payers, the financial viability of virtual-first specialty care is no longer in question. These models offer a scalable solution to the geographic and logistical barriers that have long defined specialist care in the U.S.

While challenges such as the digital divide and the limitations of a purely virtual physical exam persist, the momentum is undeniable. Partnerships between innovative telehealth providers like Neura Health and forward-thinking pharmaceutical giants like Eli Lilly are actively reshaping the landscape. By integrating technology, specialized medical expertise, and patient-centric platform design, they are creating a new standard of care that promises to be more accessible, efficient, and effective for millions.